Adalimumab Treatments Improves Dermatology Specific Quality of Life in Severe Psoriasis Patients
“Adalimumab treatment” improves dermatology-specific and general health-related quality of life (HRQoL), as well as reducing work and activity limitations and psoriasis-related symptoms in moderate to severe psoriasis patients.
These are the conclusive findings of a study recently taken place under the leadership of Dennis Revicki from the ‘United BioSource Corporation’. This study involved in the initial 16-week period of a double-blind, 52-week, Phase III, multicenter trial. Findings of this study and the conclusions have been recently published in the journal “Journal of Dermatological Treatment”.
(more…)
